Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )

Inclusion Criteria

• •Patients were diagnosed with bone metastatic castration-resistant prostate cancer (mCRPC) per medical chart.
• •Patients were at least 18 years of age as of the first diagnosis for mCRPC.
• •Patients must have received at least one intravenous injection of Radium-223 (Xofigo).
• •First injection of Radium-223 must have started between periods
• •1-January-2014 to 30-June-2014 or 15-November-2014 to present.
• •Patients must have a minimum of 12 months documented follow-up records following last Radium-223 treatment or death within 12 months of last dose.